RESUMEN
RIP140 is a transcriptional coregulator involved in energy homeostasis and ovulation which is controlled at the transcriptional level by several nuclear receptors. We demonstrate here that RIP140 is a novel target gene of the E2F1 transcription factor. Bioinformatics analysis, gel shift assay, and chromatin immunoprecipitation demonstrate that the RIP140 promoter contains bona fide E2F response elements. In transiently transfected MCF-7 breast cancer cells, the RIP140 promoter is transactivated by overexpression of E2F1/DP1. Interestingly, RIP140 mRNA is finely regulated during cell cycle progression (5-fold increase at the G1/S and G2/M transitions). The positive regulation by E2F1 requires sequences located in the proximal region of the promoter (-73/+167), involves Sp1 transcription factors, and undergoes a negative feedback control by RIP140. Finally, we show that E2F1 participates in the induction of RIP140 expression during adipocyte differentiation. Altogether, this work identifies the RIP140 gene as a new transcriptional target of E2F1 which may explain some of the effect of E2F1 in both cancer and metabolic diseases.
Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/genética , Factor de Transcripción E2F1/genética , Proteínas Nucleares/genética , Línea Celular Tumoral , Células Cultivadas , Células HeLa , Humanos , Proteína de Interacción con Receptores Nucleares 1 , Regiones Promotoras GenéticasRESUMEN
The nuclear receptor superfamily comprises ligand-regulated transcription factors that control various developmental and physiological pathways. These receptors share a common modular structure and regulate gene expression through the recruitment of a large set of coregulatory proteins. These transcription cofactors regulate, either positively or negatively, chromatin structure and transcription initiation. One of the first proteins to be identified as a hormone-recruited cofactor was RIP140. Despite its recruitment by agonist-liganded receptors, RIP140 exhibits a strong transcriptional repressive activity which involves several inhibitory domains and different effectors. Interestingly, the RIP140 gene, located on chromosome 21 in humans, is finely regulated at the transcriptional level by various nuclear receptors. In addition, the protein undergoes several post-translational modifications which control its repressive activity. Finally, experiments performed in mice devoid of the RIP140 gene indicate that this transcriptional cofactor is essential for female fertility and energy homeostasis. RIP140 therefore appears to be an important modulator of nuclear receptor activity which could play major roles in physiological processes and hormone-dependent diseases.
RESUMEN
Receptor interacting protein (RIP) 140 is a negative transcriptional regulator of nuclear hormone receptors which is required for the maintenance of energy homeostasis and ovulation. Despite its recruitment by agonist-liganded receptors, this protein exhibits a strong repressive activity which was initially attributed to competition with coactivator binding on nuclear receptors. However, RIP140 also exerts active repression implicating the Carboxyl-terminal binding proteins (CtBPs) and histone deacetylases (HDACs). We recently demonstrated that the Carboxyl-terminal region of the molecule contains two additional silencing domains which require post-translational modifications to be fully active. In human breast cancer cells, RIP140 expression is up-regulated at the transcriptional level by various ligands of nuclear receptors. We have recently cloned the human RIP140 gene and defined the mechanism of its regulation by estrogens. In order to better characterize the role of RIP140 in hormone signaling, we have studied its interaction with the androgen receptor and demonstrated its ability to repress transcriptional regulation by androgens. RIP140 also inhibits transactivation by estrogen receptor-related receptors (ERRalpha, beta and gamma) on natural or artificial reporter genes containing different types of response elements. Surprisingly, RIP140 positively regulates ERR transactivation when the receptors are recruited to target promoters through interaction with the Sp1 transcription factor and this effect could involve titration of histone deacetylases. Altogether, these results underline that transcriptional regulation of hormone signaling by the cofactor RIP140 involves complex mechanisms relying on multiple domains and partners.
Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/fisiología , Hormonas/fisiología , Proteínas Nucleares/fisiología , Transducción de Señal , Humanos , Proteína de Interacción con Receptores Nucleares 1 , Receptores de Estrógenos/metabolismo , Transcripción GenéticaRESUMEN
Receptor interacting protein 140 (RIP140) is a negative transcriptional regulator of nuclear hormone receptors that is required for the maintenance of energy homeostasis and ovulation. In this study, we investigated the mechanisms by which RIP140 expression is controlled by estrogens in breast cancer cells. We first analyzed by real time reverse transcription-polymerase chain reaction the regulation of RIP140 mRNA accumulation by estrogen receptor (ER) ligands in MCF-7 cells. We showed that the induction by estradiol (E2) was rapid and did not affect the apparent stability of the mRNA, suggesting a direct transcriptional regulation. To further study the underlying regulatory mechanisms, we then characterized the human RIP140 gene. We identified several noncoding exons with alternative splicing and localized the promoter region more than 100 kilobases upstream from the coding exon. Although we mapped a perfect consensus estrogen response element able to bind ERalpha in gel shift and in chromatin immunoprecipitation experiments, the effect of E2 on RIP140 gene transcription was very modest. This might result at least in part from the presence of an overlapping aryl hydrocarbon receptor (AhR) binding site, which interfered with the E2 response on both the transiently transfected reporter construct and the accumulation of the endogenous RIP140 mRNA. Altogether, our data indicate that the RIP140 gene exhibits a complex structure with several noncoding exons and supports transcriptional cross-talk and feedback involving the ERalpha and AhR nuclear receptors.
Asunto(s)
Dioxinas/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Proteínas Nucleares/genética , Receptores de Estrógenos/genética , Transcripción Genética/efectos de los fármacos , Proteínas Adaptadoras Transductoras de Señales , Animales , Secuencia de Bases , Línea Celular Tumoral , ADN , Humanos , Proteína de Interacción con Receptores Nucleares 1 , ARN Mensajero/genética , Homología de Secuencia de Ácido NucleicoRESUMEN
Nuclear hormone receptors belong to a superfamily of ligand-activated transcription factors which regulate fundamental physiological processes. Their activity is controlled by a large number of coregulatory proteins which are, in most cases, recruited by nuclear receptors in the presence of ligand. RIP140 (receptor interacting protein of 140 kDa) was one of the first transcription cofactors to be identified almost ten years ago. This molecule is an atypical cofactor which interacts with agonist-liganded nuclear receptors but negatively regulates their transactivation potential. RIP140 exhibits nine leucine-rich motifs (LxxLL) which mediate the specific docking on the nuclear receptor ligand-binding domain. Transcription repression exerted by this cofactor implicates different mechanisms. Not only it involves a competition with coactivators such as those belonging to the p160 family, but also relies on active intrinsic repression through at least four different domains which allow recruitement of downstream repressors such as histone deacetylases (HDACs) or C-terminal binding proteins (CtBPs). The biological role of RIP140 has been investigated by disrupting the gene in mice. The lack of RIP140 expression in ovaries prevents follicle rupture and ovulation, rising to female infertility. In addition, this cofactor is also required for the control of fat storage and utilization through the regulation of genes involved in thermogenesis. Finally, RIP140 could play a role in the hormonal control of cancer cell proliferation by negatively regulating the activity of estrogen and retinoic acid receptors which are key actors in cancer growth. Interestingly, both estrogens and retinoic acid regulate RIP140 gene expression, revealing an increased level of complexity. In conclusion, RIP140 is an atypical transcription inhibitor which, by repressing nuclear hormone receptor activity, plays fundamental physiopathological roles.
Asunto(s)
Hormonas/fisiología , Proteínas Nucleares/fisiología , Receptores de Estrógenos/fisiología , Proteínas Adaptadoras Transductoras de Señales , Animales , Femenino , Humanos , Masculino , Proteínas Nucleares/genética , Proteína de Interacción con Receptores Nucleares 1 , Receptores de Estrógenos/genética , Transcripción GenéticaRESUMEN
In this study, we have investigated the role of C-terminal binding proteins (CtBPs) and histone deacetylases (HDACs) in the repressive activity of the nuclear receptor cofactor Receptor-Interacting Protein 140 (RIP140). We have defined the interaction of both CtBP1 and CtBP2 with RIP140 and delineated two motifs (PIDLS and PINLS) differentially required for in vitro interaction. Using different approaches (titration of endogenous CtBPs, mutagenesis and transfection in CtBP knock-out cells), we find that recruitment of CtBPs only partially explains the negative regulation exerted by RIP140. We then demonstrate that RIP140 associates in vitro not only with class I HDACs but also with class II enzymes such as HDAC5. This interaction mainly involves the N-terminus of RIP140 (residues 27-199) and two domains of HDAC5. Moreover, the two proteins functionally interfere in transfection experiments, and confocal microscopy indicates that they co-localize in the nucleus. Interestingly, using the specific HDAC inhibitor trichostatin A, we show that HDAC activity is dispensable for active transrepression by RIP140. Finally, we demonstrate that the C-terminal region of RIP140 contains two additional silencing domains and confers strong active transrepression independently of HDAC activity and CtBPs. Altogether, these data indicate that transcriptional inhibition by the cofactor RIP140 involves complex mechanisms relying on multiple domains and partners.